Novo Nordisk Battles Unapproved Drug Copies in South Africa Court

Novo Nordisk is pursuing legal action against iDexis in South Africa to stop the sale of unauthorized semaglutide copies, a key ingredient in its drugs Wegovy and Ozempic. This reflects a global push against compounded GLP-1 drugs, citing safety and regulatory concerns amid rising demand and legal infractions.

Novo Nordisk, the Danish pharmaceutical giant, is making a legal bid to stop iDexis from selling unauthorized copies of semaglutide, the active ingredient in its lucrative weight-loss and diabetes treatments, Wegovy and Ozempic.

The South African High Court is reviewing Novo's application to halt iDexis from manufacturing and distributing untested semaglutide products—crucial to patient safety, product quality, and regulatory adherence, as emphasized by Novo. Compounding, often restricted to patient-specific prescriptions, is at the legal center of this case.

This case is part of Novo’s broader effort against compounded GLP-1 drug versions worldwide. As the demand for diabetes and weight-loss medications surged, a gray market emerged in South Africa following product launches by Eli Lilly and Novo. South African authorities cited iDexis for regulatory violations, prompting product seizures and recalls.